Industry Research Reports
Home > Reports > Machinery & Equipment > PRRS Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
PRRS Vaccines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Industry: Machinery & Equipment
Published Date: 2025-05-23
Pages: 134 Pages
Report ld: 4743277
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
PRRS Vaccines Market Size(US$)
CAGR 2025-2031
3.5%
Market Size,2031
USD 527
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 429 million
Market Forecast in 2031(Value)
US$ 527 million
CAGR
3.5%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for PRRS Vaccines was estimated to be worth US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on PRRS Vaccines cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
There are two types of PRRS vaccines that are commercially available. One is a modified-live virus (MLV) vaccine and the other is a killed virus (KV) vaccine. PRRS MLV vaccine is well recognized for its protective efficacy against PRRSV that are genetically homologous to the vaccine virus.Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine is a biological product designed to prevent and control PRRS, a highly contagious viral disease that affects pigs. The vaccine works by stimulating the pig's immune system to produce a protective response against the PRRS virus, thereby reducing reproductive failures such as abortions and stillbirths in sows, as well as respiratory illness and mortality in piglets and growing pigs. PRRS vaccines are typically classified into modified live vaccines (MLVs) and inactivated vaccines, and they play a critical role in improving herd health and productivity in the swine industry worldwide.
The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.
Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.
This report aims to provide a comprehensive presentation of the global market for PRRS Vaccines, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of PRRS Vaccines by region & country, by Type, and by Application.
The PRRS Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PRRS Vaccines.
MARKET SEGMENTATION
By Company
- China Animal Husbandry Co., Ltd.
- Boehringer Ingelheim
- MSD Animal Health
- Sinopharm Animal Health
- Ceva
- Ruipu Biological
- Qilu Animal Health
- Dahuanong
- CAVAC
- Komipharm
- Agrovet
- Bioveta
- Jinyu
- Phibro Animal Health
- Tiankang
- Zoetis
- Yongshun Biological
- Pulike Biological
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Live Vaccines
- Killed Vaccines
Segment by Application
- Government Tender
- Market Sales
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of PRRS Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of PRRS Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of PRRS Vaccines in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 PRRS Vaccines Product Introduction
1.2 Global PRRS Vaccines Market Size Forecast
1.2.1 Global PRRS Vaccines Sales Value (2020-2031)
1.2.2 Global PRRS Vaccines Sales Volume (2020-2031)
1.2.3 Global PRRS Vaccines Sales Price (2020-2031)
1.3 PRRS Vaccines Market Trends & Drivers
1.3.1 PRRS Vaccines Industry Trends
1.3.2 PRRS Vaccines Market Drivers & Opportunity
1.3.3 PRRS Vaccines Market Challenges
1.3.4 PRRS Vaccines Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global PRRS Vaccines Players Revenue Ranking (2024)
2.2 Global PRRS Vaccines Revenue by Company (2020-2025)
2.3 Global PRRS Vaccines Players Sales Volume Ranking (2024)
2.4 Global PRRS Vaccines Sales Volume by Company Players (2020-2025)
2.5 Global PRRS Vaccines Average Price by Company (2020-2025)
2.6 Key Manufacturers PRRS Vaccines Manufacturing Base and Headquarters
2.7 Key Manufacturers PRRS Vaccines Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of PRRS Vaccines
2.9 PRRS Vaccines Market Competitive Analysis
2.9.1 PRRS Vaccines Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by PRRS Vaccines Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PRRS Vaccines as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Live Vaccines
3.1.2 Killed Vaccines
3.2 Global PRRS Vaccines Sales Value by Type
3.2.1 Global PRRS Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global PRRS Vaccines Sales Value, by Type (2020-2031)
3.2.3 Global PRRS Vaccines Sales Value, by Type (%) (2020-2031)
3.3 Global PRRS Vaccines Sales Volume by Type
3.3.1 Global PRRS Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global PRRS Vaccines Sales Volume, by Type (2020-2031)
3.3.3 Global PRRS Vaccines Sales Volume, by Type (%) (2020-2031)
3.4 Global PRRS Vaccines Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Government Tender
4.1.2 Market Sales
4.2 Global PRRS Vaccines Sales Value by Application
4.2.1 Global PRRS Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global PRRS Vaccines Sales Value, by Application (2020-2031)
4.2.3 Global PRRS Vaccines Sales Value, by Application (%) (2020-2031)
4.3 Global PRRS Vaccines Sales Volume by Application
4.3.1 Global PRRS Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global PRRS Vaccines Sales Volume, by Application (2020-2031)
4.3.3 Global PRRS Vaccines Sales Volume, by Application (%) (2020-2031)
4.4 Global PRRS Vaccines Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global PRRS Vaccines Sales Value by Region
5.1.1 Global PRRS Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global PRRS Vaccines Sales Value by Region (2020-2025)
5.1.3 Global PRRS Vaccines Sales Value by Region (2026-2031)
5.1.4 Global PRRS Vaccines Sales Value by Region (%), (2020-2031)
5.2 Global PRRS Vaccines Sales Volume by Region
5.2.1 Global PRRS Vaccines Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global PRRS Vaccines Sales Volume by Region (2020-2025)
5.2.3 Global PRRS Vaccines Sales Volume by Region (2026-2031)
5.2.4 Global PRRS Vaccines Sales Volume by Region (%), (2020-2031)
5.3 Global PRRS Vaccines Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America PRRS Vaccines Sales Value, 2020-2031
5.4.2 North America PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe PRRS Vaccines Sales Value, 2020-2031
5.5.2 Europe PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific PRRS Vaccines Sales Value, 2020-2031
5.6.2 Asia Pacific PRRS Vaccines Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America PRRS Vaccines Sales Value, 2020-2031
5.7.2 South America PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa PRRS Vaccines Sales Value, 2020-2031
5.8.2 Middle East & Africa PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions PRRS Vaccines Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions PRRS Vaccines Sales Value and Sales Volume
6.2.1 Key Countries/Regions PRRS Vaccines Sales Value, 2020-2031
6.2.2 Key Countries/Regions PRRS Vaccines Sales Volume, 2020-2031
6.3 United States
6.3.1 United States PRRS Vaccines Sales Value, 2020-2031
6.3.2 United States PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.3.3 United States PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe PRRS Vaccines Sales Value, 2020-2031
6.4.2 Europe PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China PRRS Vaccines Sales Value, 2020-2031
6.5.2 China PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.5.3 China PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan PRRS Vaccines Sales Value, 2020-2031
6.6.2 Japan PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea PRRS Vaccines Sales Value, 2020-2031
6.7.2 South Korea PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia PRRS Vaccines Sales Value, 2020-2031
6.8.2 Southeast Asia PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia PRRS Vaccines Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India PRRS Vaccines Sales Value, 2020-2031
6.9.2 India PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
6.9.3 India PRRS Vaccines Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 China Animal Husbandry Co., Ltd.
7.1.1 China Animal Husbandry Co., Ltd. Company Information
7.1.2 China Animal Husbandry Co., Ltd. Introduction and Business Overview
7.1.3 China Animal Husbandry Co., Ltd. PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 China Animal Husbandry Co., Ltd. PRRS Vaccines Product Offerings
7.1.5 China Animal Husbandry Co., Ltd. Recent Development
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Information
7.2.2 Boehringer Ingelheim Introduction and Business Overview
7.2.3 Boehringer Ingelheim PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Boehringer Ingelheim PRRS Vaccines Product Offerings
7.2.5 Boehringer Ingelheim Recent Development
7.3 MSD Animal Health
7.3.1 MSD Animal Health Company Information
7.3.2 MSD Animal Health Introduction and Business Overview
7.3.3 MSD Animal Health PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 MSD Animal Health PRRS Vaccines Product Offerings
7.3.5 MSD Animal Health Recent Development
7.4 Sinopharm Animal Health
7.4.1 Sinopharm Animal Health Company Information
7.4.2 Sinopharm Animal Health Introduction and Business Overview
7.4.3 Sinopharm Animal Health PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Sinopharm Animal Health PRRS Vaccines Product Offerings
7.4.5 Sinopharm Animal Health Recent Development
7.5 Ceva
7.5.1 Ceva Company Information
7.5.2 Ceva Introduction and Business Overview
7.5.3 Ceva PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Ceva PRRS Vaccines Product Offerings
7.5.5 Ceva Recent Development
7.6 Ruipu Biological
7.6.1 Ruipu Biological Company Information
7.6.2 Ruipu Biological Introduction and Business Overview
7.6.3 Ruipu Biological PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Ruipu Biological PRRS Vaccines Product Offerings
7.6.5 Ruipu Biological Recent Development
7.7 Qilu Animal Health
7.7.1 Qilu Animal Health Company Information
7.7.2 Qilu Animal Health Introduction and Business Overview
7.7.3 Qilu Animal Health PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Qilu Animal Health PRRS Vaccines Product Offerings
7.7.5 Qilu Animal Health Recent Development
7.8 Dahuanong
7.8.1 Dahuanong Company Information
7.8.2 Dahuanong Introduction and Business Overview
7.8.3 Dahuanong PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Dahuanong PRRS Vaccines Product Offerings
7.8.5 Dahuanong Recent Development
7.9 CAVAC
7.9.1 CAVAC Company Information
7.9.2 CAVAC Introduction and Business Overview
7.9.3 CAVAC PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 CAVAC PRRS Vaccines Product Offerings
7.9.5 CAVAC Recent Development
7.10 Komipharm
7.10.1 Komipharm Company Information
7.10.2 Komipharm Introduction and Business Overview
7.10.3 Komipharm PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Komipharm PRRS Vaccines Product Offerings
7.10.5 Komipharm Recent Development
7.11 Agrovet
7.11.1 Agrovet Company Information
7.11.2 Agrovet Introduction and Business Overview
7.11.3 Agrovet PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Agrovet PRRS Vaccines Product Offerings
7.11.5 Agrovet Recent Development
7.12 Bioveta
7.12.1 Bioveta Company Information
7.12.2 Bioveta Introduction and Business Overview
7.12.3 Bioveta PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Bioveta PRRS Vaccines Product Offerings
7.12.5 Bioveta Recent Development
7.13 Jinyu
7.13.1 Jinyu Company Information
7.13.2 Jinyu Introduction and Business Overview
7.13.3 Jinyu PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Jinyu PRRS Vaccines Product Offerings
7.13.5 Jinyu Recent Development
7.14 Phibro Animal Health
7.14.1 Phibro Animal Health Company Information
7.14.2 Phibro Animal Health Introduction and Business Overview
7.14.3 Phibro Animal Health PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Phibro Animal Health PRRS Vaccines Product Offerings
7.14.5 Phibro Animal Health Recent Development
7.15 Tiankang
7.15.1 Tiankang Company Information
7.15.2 Tiankang Introduction and Business Overview
7.15.3 Tiankang PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.15.4 Tiankang PRRS Vaccines Product Offerings
7.15.5 Tiankang Recent Development
7.16 Zoetis
7.16.1 Zoetis Company Information
7.16.2 Zoetis Introduction and Business Overview
7.16.3 Zoetis PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.16.4 Zoetis PRRS Vaccines Product Offerings
7.16.5 Zoetis Recent Development
7.17 Yongshun Biological
7.17.1 Yongshun Biological Company Information
7.17.2 Yongshun Biological Introduction and Business Overview
7.17.3 Yongshun Biological PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.17.4 Yongshun Biological PRRS Vaccines Product Offerings
7.17.5 Yongshun Biological Recent Development
7.18 Pulike Biological
7.18.1 Pulike Biological Company Information
7.18.2 Pulike Biological Introduction and Business Overview
7.18.3 Pulike Biological PRRS Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.18.4 Pulike Biological PRRS Vaccines Product Offerings
7.18.5 Pulike Biological Recent Development
8 Industry Chain Analysis
8.1 PRRS Vaccines Industrial Chain
8.2 PRRS Vaccines Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 PRRS Vaccines Sales Model
8.5.2 Sales Channel
8.5.3 PRRS Vaccines Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. PRRS Vaccines Market Trends
Table 2. PRRS Vaccines Market Drivers & Opportunity
Table 3. PRRS Vaccines Market Challenges
Table 4. PRRS Vaccines Market Restraints
Table 5. Global PRRS Vaccines Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global PRRS Vaccines Revenue Market Share by Company (2020-2025)
Table 7. Global PRRS Vaccines Sales Volume by Company (2020-2025) & (K Units)
Table 8. Global PRRS Vaccines Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market PRRS Vaccines Price by Company (2020-2025) & (USD/Unit)
Table 10. Key Manufacturers PRRS Vaccines Manufacturing Base and Headquarters
Table 11. Key Manufacturers PRRS Vaccines Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of PRRS Vaccines
Table 13. Global PRRS Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PRRS Vaccines as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global PRRS Vaccines Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global PRRS Vaccines Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global PRRS Vaccines Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global PRRS Vaccines Sales Market Share in Value by Type (2020-2025)
Table 20. Global PRRS Vaccines Sales Market Share in Value by Type (2026-2031)
Table 21. Global PRRS Vaccines Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
Table 22. Global PRRS Vaccines Sales Volume by Type (2020-2025) & (K Units)
Table 23. Global PRRS Vaccines Sales Volume by Type (2026-2031) & (K Units)
Table 24. Global PRRS Vaccines Sales Market Share in Volume by Type (2020-2025)
Table 25. Global PRRS Vaccines Sales Market Share in Volume by Type (2026-2031)
Table 26. Global PRRS Vaccines Price by Type (2020-2025) & (USD/Unit)
Table 27. Global PRRS Vaccines Price by Type (2026-2031) & (USD/Unit)
Table 28. Global PRRS Vaccines Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global PRRS Vaccines Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global PRRS Vaccines Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global PRRS Vaccines Sales Market Share in Value by Application (2020-2025)
Table 32. Global PRRS Vaccines Sales Market Share in Value by Application (2026-2031)
Table 33. Global PRRS Vaccines Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
Table 34. Global PRRS Vaccines Sales Volume by Application (2020-2025) & (K Units)
Table 35. Global PRRS Vaccines Sales Volume by Application (2026-2031) & (K Units)
Table 36. Global PRRS Vaccines Sales Market Share in Volume by Application (2020-2025)
Table 37. Global PRRS Vaccines Sales Market Share in Volume by Application (2026-2031)
Table 38. Global PRRS Vaccines Price by Application (2020-2025) & (USD/Unit)
Table 39. Global PRRS Vaccines Price by Application (2026-2031) & (USD/Unit)
Table 40. Global PRRS Vaccines Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global PRRS Vaccines Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global PRRS Vaccines Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global PRRS Vaccines Sales Value by Region (2020-2025) & (%)
Table 44. Global PRRS Vaccines Sales Value by Region (2026-2031) & (%)
Table 45. Global PRRS Vaccines Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
Table 46. Global PRRS Vaccines Sales Volume by Region (2020-2025) & (K Units)
Table 47. Global PRRS Vaccines Sales Volume by Region (2026-2031) & (K Units)
Table 48. Global PRRS Vaccines Sales Volume by Region (2020-2025) & (%)
Table 49. Global PRRS Vaccines Sales Volume by Region (2026-2031) & (%)
Table 50. Global PRRS Vaccines Average Price by Region (2020-2025) & (USD/Unit)
Table 51. Global PRRS Vaccines Average Price by Region (2026-2031) & (USD/Unit)
Table 52. Key Countries/Regions PRRS Vaccines Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions PRRS Vaccines Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions PRRS Vaccines Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions PRRS Vaccines Sales Volume, (2020-2025) & (K Units)
Table 56. Key Countries/Regions PRRS Vaccines Sales Volume, (2026-2031) & (K Units)
Table 57. China Animal Husbandry Co., Ltd. Company Information
Table 58. China Animal Husbandry Co., Ltd. Introduction and Business Overview
Table 59. China Animal Husbandry Co., Ltd. PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 60. China Animal Husbandry Co., Ltd. PRRS Vaccines Product Offerings
Table 61. China Animal Husbandry Co., Ltd. Recent Development
Table 62. Boehringer Ingelheim Company Information
Table 63. Boehringer Ingelheim Introduction and Business Overview
Table 64. Boehringer Ingelheim PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 65. Boehringer Ingelheim PRRS Vaccines Product Offerings
Table 66. Boehringer Ingelheim Recent Development
Table 67. MSD Animal Health Company Information
Table 68. MSD Animal Health Introduction and Business Overview
Table 69. MSD Animal Health PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 70. MSD Animal Health PRRS Vaccines Product Offerings
Table 71. MSD Animal Health Recent Development
Table 72. Sinopharm Animal Health Company Information
Table 73. Sinopharm Animal Health Introduction and Business Overview
Table 74. Sinopharm Animal Health PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 75. Sinopharm Animal Health PRRS Vaccines Product Offerings
Table 76. Sinopharm Animal Health Recent Development
Table 77. Ceva Company Information
Table 78. Ceva Introduction and Business Overview
Table 79. Ceva PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Ceva PRRS Vaccines Product Offerings
Table 81. Ceva Recent Development
Table 82. Ruipu Biological Company Information
Table 83. Ruipu Biological Introduction and Business Overview
Table 84. Ruipu Biological PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 85. Ruipu Biological PRRS Vaccines Product Offerings
Table 86. Ruipu Biological Recent Development
Table 87. Qilu Animal Health Company Information
Table 88. Qilu Animal Health Introduction and Business Overview
Table 89. Qilu Animal Health PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 90. Qilu Animal Health PRRS Vaccines Product Offerings
Table 91. Qilu Animal Health Recent Development
Table 92. Dahuanong Company Information
Table 93. Dahuanong Introduction and Business Overview
Table 94. Dahuanong PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 95. Dahuanong PRRS Vaccines Product Offerings
Table 96. Dahuanong Recent Development
Table 97. CAVAC Company Information
Table 98. CAVAC Introduction and Business Overview
Table 99. CAVAC PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 100. CAVAC PRRS Vaccines Product Offerings
Table 101. CAVAC Recent Development
Table 102. Komipharm Company Information
Table 103. Komipharm Introduction and Business Overview
Table 104. Komipharm PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 105. Komipharm PRRS Vaccines Product Offerings
Table 106. Komipharm Recent Development
Table 107. Agrovet Company Information
Table 108. Agrovet Introduction and Business Overview
Table 109. Agrovet PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 110. Agrovet PRRS Vaccines Product Offerings
Table 111. Agrovet Recent Development
Table 112. Bioveta Company Information
Table 113. Bioveta Introduction and Business Overview
Table 114. Bioveta PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 115. Bioveta PRRS Vaccines Product Offerings
Table 116. Bioveta Recent Development
Table 117. Jinyu Company Information
Table 118. Jinyu Introduction and Business Overview
Table 119. Jinyu PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 120. Jinyu PRRS Vaccines Product Offerings
Table 121. Jinyu Recent Development
Table 122. Phibro Animal Health Company Information
Table 123. Phibro Animal Health Introduction and Business Overview
Table 124. Phibro Animal Health PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 125. Phibro Animal Health PRRS Vaccines Product Offerings
Table 126. Phibro Animal Health Recent Development
Table 127. Tiankang Company Information
Table 128. Tiankang Introduction and Business Overview
Table 129. Tiankang PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 130. Tiankang PRRS Vaccines Product Offerings
Table 131. Tiankang Recent Development
Table 132. Zoetis Company Information
Table 133. Zoetis Introduction and Business Overview
Table 134. Zoetis PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 135. Zoetis PRRS Vaccines Product Offerings
Table 136. Zoetis Recent Development
Table 137. Yongshun Biological Company Information
Table 138. Yongshun Biological Introduction and Business Overview
Table 139. Yongshun Biological PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 140. Yongshun Biological PRRS Vaccines Product Offerings
Table 141. Yongshun Biological Recent Development
Table 142. Pulike Biological Company Information
Table 143. Pulike Biological Introduction and Business Overview
Table 144. Pulike Biological PRRS Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 145. Pulike Biological PRRS Vaccines Product Offerings
Table 146. Pulike Biological Recent Development
Table 147. Key Raw Materials Lists
Table 148. Raw Materials Key Suppliers Lists
Table 149. PRRS Vaccines Downstream Customers
Table 150. PRRS Vaccines Distributors List
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. PRRS Vaccines Product Picture
Figure 2. Global PRRS Vaccines Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global PRRS Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 4. Global PRRS Vaccines Sales Volume (2020-2031) & (K Units)
Figure 5. Global PRRS Vaccines Sales Price (2020-2031) & (USD/Unit)
Figure 6. PRRS Vaccines Report Years Considered
Figure 7. Global PRRS Vaccines Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global PRRS Vaccines Players Sales Volume Ranking (2024) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by PRRS Vaccines Revenue in 2024
Figure 10. PRRS Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. Live Vaccines Picture
Figure 12. Killed Vaccines Picture
Figure 13. Global PRRS Vaccines Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 14. Global PRRS Vaccines Sales Value Market Share by Type, 2024 & 2031
Figure 15. Global PRRS Vaccines Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
Figure 16. Global PRRS Vaccines Sales Volume Market Share by Type, 2024 & 2031
Figure 17. Global PRRS Vaccines Price by Type (2020-2031) & (USD/Unit)
Figure 18. Product Picture of Government Tender
Figure 19. Product Picture of Market Sales
Figure 20. Global PRRS Vaccines Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 21. Global PRRS Vaccines Sales Value Market Share by Application, 2024 & 2031
Figure 22. Global PRRS Vaccines Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
Figure 23. Global PRRS Vaccines Sales Volume Market Share by Application, 2024 & 2031
Figure 24. Global PRRS Vaccines Price by Application (2020-2031) & (USD/Unit)
Figure 25. North America PRRS Vaccines Sales Value (2020-2031) & (US$ Million)
Figure 26. North America PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
Figure 27. Europe PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 28. Europe PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
Figure 29. Asia Pacific PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 30. Asia Pacific PRRS Vaccines Sales Value by Region (%), 2024 VS 2031
Figure 31. South America PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 32. South America PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
Figure 33. Middle East & Africa PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 34. Middle East & Africa PRRS Vaccines Sales Value by Country (%), 2024 VS 2031
Figure 35. Key Countries/Regions PRRS Vaccines Sales Value (%), (2020-2031)
Figure 36. Key Countries/Regions PRRS Vaccines Sales Volume (%), (2020-2031)
Figure 37. United States PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 38. United States PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
Figure 39. United States PRRS Vaccines Sales Value by Application (%), 2024 VS 2031
Figure 40. Europe PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 41. Europe PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
Figure 42. Europe PRRS Vaccines Sales Value by Application (%), 2024 VS 2031
Figure 43. China PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 44. China PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
Figure 45. China PRRS Vaccines Sales Value by Application (%), 2024 VS 2031
Figure 46. Japan PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 47. Japan PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
Figure 48. Japan PRRS Vaccines Sales Value by Application (%), 2024 VS 2031
Figure 49. South Korea PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 50. South Korea PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
Figure 51. South Korea PRRS Vaccines Sales Value by Application (%), 2024 VS 2031
Figure 52. Southeast Asia PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 53. Southeast Asia PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
Figure 54. Southeast Asia PRRS Vaccines Sales Value by Application (%), 2024 VS 2031
Figure 55. India PRRS Vaccines Sales Value, (2020-2031) & (US$ Million)
Figure 56. India PRRS Vaccines Sales Value by Type (%), 2024 VS 2031
Figure 57. India PRRS Vaccines Sales Value by Application (%), 2024 VS 2031
Figure 58. PRRS Vaccines Industrial Chain
Figure 59. PRRS Vaccines Manufacturing Cost Structure
Figure 60. Channels of Distribution (Direct Sales, and Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global PRRS Vaccines market?
The top companies in the global PRRS Vaccines market are China Animal Husbandry Co., Ltd.、Boehringer Ingelheim、MSD Animal Health.
Which region is expected to have the highest market share?
What is the annual compound growth rate of the global PRRS Vaccines market size from 2025 to 2031?
What was the global market size of PRRS Vaccines in 2031?
What was the global market size of PRRS Vaccines in 2025?
Related Reports
Global PRRS Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global PRRS Vaccines market size was US$ 429 million in 2025 and is forecast to reach a readjusted size of US$ 543 million by 2032 with a CAGR of 3.5% during the forecast period 2026-2032.
Published Date: 2026-03-09
Pages: 104
USD 4250.00
(Single User License)
Global PRRS Vaccines Market Outlook, In‑Depth Analysis & Forecast to 2032
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 543 million by 2032, at a CAGR of 3.5% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-03-09
Pages: 179
USD 4900.00
(Single User License)
PRRS Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for PRRS Vaccines was estimated to be worth US$ 429 million in 2025 and is projected to reach US$ 543 million, growing at a CAGR of 3.5% from 2026 to 2032.
Published Date: 2026-03-05
Pages: 131
USD 3950.00
(Single User License)
Global PRRS Vaccines Market Research Report 2026
The global PRRS Vaccines market was valued at US$ 429 million in 2025 and is anticipated to reach US$ 543 million by 2032, at a CAGR of 3.5% from 2026 to 2032.
Published Date: 2026-03-05
Pages: 146
USD 2900.00
(Single User License)
Global PRRS Vaccines Market Outlook, In‑Depth Analysis & Forecast to 2031
The global PRRS Vaccines market is projected to grow from US$ 410 million in 2024 to US$ 527 million by 2031, at a CAGR of 3.5% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-30
Pages: 176
USD 4900.00
(Single User License)
Global PRRS Vaccines Market Insights, Forecast to 2031
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 527 million by 2031, at a Compound Annual Growth Rate (CAGR) of 3.5% during the forecast period.
Published Date: 2025-05-23
Pages: 175
USD 4900.00
(Single User License)
Global PRRS Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global PRRS Vaccines market size was US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published Date: 2025-05-23
Pages: 109
USD 4250.00
(Single User License)
Global PRRS Vaccines Market Research Report 2025
The global market for PRRS Vaccines was valued at US$ 410 million in the year 2024 and is projected to reach a revised size of US$ 527 million by 2031, growing at a CAGR of 3.5% during the forecast period.
Published Date: 2025-05-23
Pages: 115
USD 2900.00
(Single User License)
PRRS Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for PRRS Vaccines was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 140
USD 3950.00
(Single User License)
Global PRRS Vaccines Market Insights, Forecast to 2030
There are two types of PRRS vaccines that are commercially available. One is a modified-live virus (MLV) vaccine and the other is a killed virus (KV) vaccine. PRRS MLV vaccine is well recognized for its protective efficacy against PRRSV that are genetically homologous to the vaccine virus.
Published Date: 2024-04-22
Pages: 117
USD 4900.00
(Single User License)
Global PRRS Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global PRRS Vaccines market size was US$ 429 million in 2025 and is forecast to reach a readjusted size of US$ 543 million by 2032 with a CAGR of 3.5% during the forecast period 2026-2032.
Published: 2026-03-09
Pages: 104
USD 4250.00 (Single User License)Global PRRS Vaccines Market Outlook, In‑Depth Analysis & Forecast to 2032
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 543 million by 2032, at a CAGR of 3.5% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-03-09
Pages: 179
USD 4900.00 (Single User License)PRRS Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for PRRS Vaccines was estimated to be worth US$ 429 million in 2025 and is projected to reach US$ 543 million, growing at a CAGR of 3.5% from 2026 to 2032.
Published: 2026-03-05
Pages: 131
USD 3950.00 (Single User License)Global PRRS Vaccines Market Research Report 2026
The global PRRS Vaccines market was valued at US$ 429 million in 2025 and is anticipated to reach US$ 543 million by 2032, at a CAGR of 3.5% from 2026 to 2032.
Published: 2026-03-05
Pages: 146
USD 2900.00 (Single User License)Global PRRS Vaccines Market Outlook, In‑Depth Analysis & Forecast to 2031
The global PRRS Vaccines market is projected to grow from US$ 410 million in 2024 to US$ 527 million by 2031, at a CAGR of 3.5% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-30
Pages: 176
USD 4900.00 (Single User License)Global PRRS Vaccines Market Insights, Forecast to 2031
The global PRRS Vaccines market is projected to grow from US$ 429 million in 2025 to US$ 527 million by 2031, at a Compound Annual Growth Rate (CAGR) of 3.5% during the forecast period.
Published: 2025-05-23
Pages: 175
USD 4900.00 (Single User License)Global PRRS Vaccines Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global PRRS Vaccines market size was US$ 410 million in 2024 and is forecast to a readjusted size of US$ 527 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.
Published: 2025-05-23
Pages: 109
USD 4250.00 (Single User License)Global PRRS Vaccines Market Research Report 2025
The global market for PRRS Vaccines was valued at US$ 410 million in the year 2024 and is projected to reach a revised size of US$ 527 million by 2031, growing at a CAGR of 3.5% during the forecast period.
Published: 2025-05-23
Pages: 115
USD 2900.00 (Single User License)PRRS Vaccines- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for PRRS Vaccines was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 140
USD 3950.00 (Single User License)Global PRRS Vaccines Market Insights, Forecast to 2030
There are two types of PRRS vaccines that are commercially available. One is a modified-live virus (MLV) vaccine and the other is a killed virus (KV) vaccine. PRRS MLV vaccine is well recognized for its protective efficacy against PRRSV that are genetically homologous to the vaccine virus.
Published: 2024-04-22
Pages: 117
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now